{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T02:07:00Z","timestamp":1775182020898,"version":"3.50.1"},"reference-count":20,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2024,11,11]],"date-time":"2024-11-11T00:00:00Z","timestamp":1731283200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100021515","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100021515","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009857","name":"Regeneron Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009857","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pediatric Dermatology"],"published-print":{"date-parts":[[2025,3]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To evaluate long\u2010term infection rates in children aged 6\u2009months to 5\u2009years with moderate\u2010to\u2010severe atopic dermatitis (AD) treated with dupilumab.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This was a post hoc analysis of an ongoing open\u2010label extension (OLE) study of dupilumab. Pediatric patients aged 6\u2009months to 5\u2009years with moderate\u2010to\u2010severe AD who had previously taken part in the LIBERTY AD PRESCHOOL phase 2 and 3 clinical trials received weight\u2010based subcutaneous dupilumab every 2 or 4\u2009weeks. Exposure\u2010adjusted infection rates after a median dupilumab exposure of 52\u2009weeks are compared with data from the earlier randomized, placebo\u2010controlled, 16\u2010week LIBERTY AD PRESCHOOL phase 3 trial.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Infection rates were overall lower in the OLE study compared with the dupilumab and placebo groups in the earlier 16\u2010week trial, including total infections (101.0 patients\/100 patient\u2010years [PY]), nonherpetic skin infections (22.7 patients\/100PY), herpetic infections (7.3 patients\/100PY), and nonskin infections (92.9 patients\/100PY). The frequency of severe and serious infections was low (3.1 patients\/100PY), compared with 17.1 placebo\u2010treated patients\/100PY and 0 dupilumab\u2010treated patients in the earlier 16\u2010week trial, and no infections leading to treatment discontinuation were observed. Systemic anti\u2010infective medication use (58.9 patients\/100PY) was lower in the OLE study compared with both the dupilumab and placebo groups in the 16\u2010week trial.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Overall, reduced infection rates are observed in infants and young children with moderate\u2010to\u2010severe AD treated with dupilumab long\u2010term, supporting the known safety profile of dupilumab.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/pde.15781","type":"journal-article","created":{"date-parts":[[2024,11,12]],"date-time":"2024-11-12T01:05:13Z","timestamp":1731373513000},"page":"251-258","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Low Infection Rates With Long\u2010Term Dupilumab Treatment in Patients Aged 6\u2009Months to 5\u2009Years: An Open\u2010Label Extension Study"],"prefix":"10.1111","volume":"42","author":[{"given":"Amy S.","family":"Paller","sequence":"first","affiliation":[{"name":"Department of Dermatology Northwestern University Feinberg School of Medicine  Chicago Illinois USA"},{"name":"Ann and Robert H. Lurie Children's Hospital  Chicago Illinois USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9191-3611","authenticated-orcid":false,"given":"Michele","family":"Ramien","sequence":"additional","affiliation":[{"name":"Division of Dermatology, Department of Medicine University of Calgary  Calgary Alberta Canada"},{"name":"Section of Community Pediatrics, Department of Pediatrics Alberta Children's Hospital  Calgary Alberta Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael J.","family":"Cork","sequence":"additional","affiliation":[{"name":"Sheffield Dermatology Research University of Sheffield  Sheffield UK"},{"name":"Sheffield Children's Hospital  Sheffield UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric L.","family":"Simpson","sequence":"additional","affiliation":[{"name":"Department of Dermatology Oregon Health &amp; Science University  Portland Oregon USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lara","family":"Wine Lee","sequence":"additional","affiliation":[{"name":"Dermatology and Dermatologic Surgery Medical University of South Carolina  Charleston South Carolina USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lawrence F.","family":"Eichenfield","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Pediatrics University\u00a0of\u00a0California San Diego  La Jolla California USA"},{"name":"Division of Pediatric and Adolescent Dermatology Rady Children's Hospital  San Diego California USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Faisal A.","family":"Khokhar","sequence":"additional","affiliation":[{"name":"Regeneron Pharmaceuticals Inc.  Tarrytown New York USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Coleman","sequence":"additional","affiliation":[{"name":"Regeneron Pharmaceuticals Inc.  Dublin Ireland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guy","family":"Gherardi","sequence":"additional","affiliation":[{"name":"Sanofi  Reading UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhen","family":"Chen","sequence":"additional","affiliation":[{"name":"Regeneron Pharmaceuticals Inc.  Tarrytown New York USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annie","family":"Zhang","sequence":"additional","affiliation":[{"name":"Sanofi  Cambridge Massachusetts USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7231-0054","authenticated-orcid":false,"given":"Sonya L.","family":"Cyr","sequence":"additional","affiliation":[{"name":"Regeneron Pharmaceuticals Inc.  Tarrytown New York USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2024,11,11]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2006.03.046"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines9030303"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.sder.2012.07.006"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2013.08.012"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12016\u2010016\u20108548\u20105"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2023.05.026"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/all.14151"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2014.11.001"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140\u20106736(22)01539\u20102"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40257\u2010024\u201000859\u2010y"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40272\u2010023\u201000611\u20109"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.16928"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/pde.14909"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2023.05.025"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13555\u2010022\u201000737\u20107"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1080\/1744666X.2022.2014323"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2019.05.073"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2020.09.084"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/all.15742"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40257\u2010019\u201000445\u20107"}],"container-title":["Pediatric Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/pde.15781","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T10:03:20Z","timestamp":1765533800000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/pde.15781"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,11]]},"references-count":20,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["10.1111\/pde.15781"],"URL":"https:\/\/doi.org\/10.1111\/pde.15781","archive":["Portico"],"relation":{},"ISSN":["0736-8046","1525-1470"],"issn-type":[{"value":"0736-8046","type":"print"},{"value":"1525-1470","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,11]]},"assertion":[{"value":"2024-07-25","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-09-29","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-11-11","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}